GIFT: Genotype Information and Functional Testing Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Scripps Health
- Enrollment
- 2,000
- Locations
- 1
- Primary Endpoint
- residual platelet reactivity
Study Overview
Brief Summary
This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Detailed Description
AS DESCRIBED BY THE PI: This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS randomization/selection determination
Exclusion Criteria
- •See GRAVITAS trial (ClinicalTrials.gov identifier: NCT00645918)
Outcomes
Primary Outcomes
residual platelet reactivity
Time Frame: 6 months
Outcome 1 is residual platelet reactivity the measurement
Secondary Outcomes
No secondary outcomes reported